Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression

EJNMMI Research

Original Research

Ulrike Garske-Román¹  Mattias Sandström²  Mark Lubberink²  Anders Sundin³  Ulrika Jahn³ 

[1] Department of Blood and Tumor Diseases, Uppsala University Hospital, Uppsala, Sweden;Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden;Department of Surgical Sciences, Nuclear Medicine and PET, Uppsala University Hospital, 751 85, Uppsala, Sweden;Department of Medical Physics, Uppsala University Hospital, Uppsala, Sweden;Department of Surgical Sciences, Nuclear Medicine and PET, Uppsala University Hospital, 751 85, Uppsala, Sweden;Medical Imaging Centre, Uppsala University Hospital, Uppsala, Sweden;

关键词: Peptide;    SUV;    Small intestinal NET;    Pancreatic NET;    Somatostatin receptor;    PRRT;   

DOI  :  10.1186/s13550-023-00997-0

 received in 2023-03-08, accepted in 2023-05-08,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundThe accumulation of 177Lu-DOTATATE might be influenced by the amount of administered peptide in relation to the tumor somatostatin receptor expression. The effect of the administered peptide mass on the resulting absorbed dose in tumors and normal organs has not previously been assessed in relation to the patients’ tumor load.MethodPatients with small intestinal (n = 141) and pancreatic (n = 62) neuroendocrine tumors (NETs) who underwent PRRT were selected for retrospective evaluation. All patients had received 7.4 GBq 177Lu-DOTATATE, and the amount of administered peptide in the preparation varied from 93 to 456 µg. The absorbed dose in tumors and normal tissue at the first PRRT cycle was calculated, based on SPECT-measurements at day 1, 4, and 7 post-infusion. The total tumor somatostatin receptor expression (tTSSTRE) was calculated on SPECT after 24 h by multiplying the functional tumor volume, delineated by 42% cut-off VOIs of the highest activity, with the SUVmean for the respective tumor VOIs. Spearman’s rank correlation analyzed any relationship between the administered amount of peptide and the absorbed dose in tumors and normal organs, in relation to the patients’ tTSSTRE.ResultsThere was no correlation between the amount of peptide and any of the tested parameters in relation to tTSSTRE.ConclusionIn this retrospective analysis, no correlation between the amount of administered peptide in the 177Lu-DOTATATE preparation and the absorbed radiation doses in tumors and normal tissues was demonstrated in relation to the total tumor SSTR expression.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2023_36_Article_IEq487.gif

Fig. 3